Prognostic Factors after Nonmyeloablative Allogeneic Stem Transplantation (NST) in Chronic Lymphocytic Leukemia (CLL): Expression of P53 May Not Predict Survival

被引：0
|
作者：
Khouri, Issa
Bassett, Roland L. [1 ]
Hsu, Yvonne
Dickason, Timothy [2 ]
Acholonu, Sandra
Harrell, Robyn [1 ]
Okoroji, Grace-Julia
Silva, Leandro de Padua
Korbling, Martin J.
Alousi, Amin M.
Hosing, Chitra
Popat, Uday
Giralt, Sergio A.
Kebriaei, Partow
Qazilbash, Muzaffar H.
Ledesma, Celina
Keating, Michael J. [3 ]
Champlin, Richard E.
Bueso-Ramos, Carlos [3 ]
机构：
[1] Univ Texas MD Anderson Canc Ctr, Div Quantitat Sci, Houston, TX 77030 USA
[2] Univ Texas MD Anderson Canc Ctr, Dept Hematopathol, Houston, TX 77030 USA
[3] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA
来源：
BLOOD | 2008年 / 112卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：412 / 412
页数：1
相关论文
共 50 条
  • [1] Prognostic factors for survival after autologous and allogeneic stem cell transplantation for Chronic Lymphocytic Leukemia (CLL): The EBMT experience
    Michallet, M
    Brand, R
    Dreger, P
    Milligan, DW
    Esteve, J
    Kimby, E
    Gratwohl, A
    Apperley, J
    Van Biezen, A
    Niederwieser, D
    [J]. BONE MARROW TRANSPLANTATION, 2001, 27 : S31 - S31
  • [2] Impact of rituximab on immunomodulation and survival after non-myeloablative allogeneic stem cell transplantation (NST) for chronic lymphocytic leukemia (CLL).
    Khouri, IF
    Lee, MS
    Saliba, RM
    Korbling, M
    McMannis, JD
    Keating, MJ
    Champlin, RE
    [J]. BLOOD, 2003, 102 (11) : 727A - 727A
  • [3] A prognostic model for survival in patients with chronic lymphocytic leukemia (CLL) based on degree of P53 expression.
    Giles, F
    O'Brien, S
    Bekele, B
    Thomas, D
    Cortes, J
    Faderl, S
    Zhou, X
    Kantarjian, H
    Keating, M
    Albitar, M
    [J]. BLOOD, 2001, 98 (11) : 282B - 283B
  • [4] FEASIBILITY OF LENALIDOMIDE MAINTENANCE AFTER NONMYELOABLATIVE ALLOGENEIC TRANSPLANTATION (NMAT) IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
    Khouri, I.
    Gulbis, A.
    Ledesma, C.
    Korbling, M.
    Turturro, F.
    Bueso-Ramos, C.
    Jabbour, E.
    Bassett, R., Jr.
    [J]. HAEMATOLOGICA, 2015, 100 : 283 - 284
  • [5] Prognostic factors for survival after autologous stem cell transplantation for chronic lymphocytic leukemia (CLL): The EBMT experience.
    Dreger, P
    van Biezen, A
    Brand, R
    Esteve, J
    Gratwohl, A
    Kimby, E
    Michallet, M
    Milligan, DW
    Niederwieser, D
    [J]. BLOOD, 2000, 96 (11) : 482A - 482A
  • [6] Stem cell transplantation (SCT) for chronic lymphocytic leukemia (CLL):: Outcome and prognostic factors after autologous and allogeneic transplants.
    Esteve, J
    Montserrat, E
    Dreger, P
    Meloni, G
    Pavletic, S
    Catovsky, D
    Dearden, C
    Scimè, R
    Sutton, L
    Michallet, M
    Desablens, B
    Kimby, E
    Coiffier, B
    Brunet, S
    Sanz, MA
    Besalduch, J
    Caballero, D
    Juliusson, G
    Conde, E
    del Potro, E
    Schmitz, N
    [J]. BLOOD, 2001, 98 (11) : 482A - 482A
  • [7] Prognostic Factors for Outcome of Nonmyeloablative Allogeneic Stem Cell Transplantation (NST) in Poor-Risk Chronic Lymphocytic Leukemia (CLL): Final Results from a Prospective Multicenter Trial (GCLLSG CLL3X study)
    Dreger, Peter
    Stilgenbauer, Stephan
    Boettcher, Sebastian
    Ritgen, Matthias
    Dietrich, Sascha
    Bunjes, Donald
    Beelen, Dietrich Wilhelm
    Cohen, Sandra
    Hegenbart, Ute
    Schubert, Joerg
    Stadler, Michael
    Glass, Bertram
    Burchert, Andreas
    Uharek, Lutz
    Hallek, Michael
    Kneba, Michael
    Schmitz, Norbert
    Doehner, Hartmut
    [J]. BLOOD, 2008, 112 (11) : 212 - 212
  • [8] Feasibility Analysis of Nonmyeloabltive Allogeneic Stem Cell Transplantation (NST) in Patients with Chronic Lymphocytic Leukemia (CLL) and 17p-Deletion
    Hsu, Yvonne
    Saliba, Rima M.
    Okoroji, Grace-Julia
    O'Brien, Susan
    Ferrajoli, Alessandra
    Abruzzo, Lynne V.
    Champlin, Richard
    Keating, Michael J.
    Khouri, Issa F.
    [J]. BLOOD, 2011, 118 (21) : 1763 - 1763
  • [9] ZAP-70 status does not predict outcome after nonmyeloablative allogeneic stem-cell transplantation (NST) in relapsed/refractory chronic lymphocytic leukemia (CLL) that fails to respond to conventional chemoimmunotherapy.
    Khouri, Issa F.
    Saliba, Rima M.
    Admirand, Joan
    O'Brien, Susan
    Lee, Ming-S.
    Samuels, Barry I.
    Giralt, Sergio
    de Lima, Marcos
    Keating, Michael J.
    Champlin, Richard E.
    Bueso-Ramos, Carlos
    [J]. BLOOD, 2006, 108 (11) : 860A - 860A
  • [10] Allogeneic hematopoietic stem cell transplantation (HSCT) for chronic lymphocytic leukemia (CLL): Results and prognostic factors for survival after transplantation. Analysis from EBMT registry.
    Michallet, M
    Brand, R
    Dreger, P
    Millighan, D
    Esteve, J
    Kimby, E
    Apperley, J
    Van Biezen, A
    Niederwieser, D
    [J]. BLOOD, 2000, 96 (11) : 205A - 205A
12345